Recursion Pharmaceuticals, Inc. RXRX Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s deferred revenue?
- Recursion Pharmaceuticals, Inc. (RXRX) reported deferred revenue of $32.79M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s deferred revenue changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s deferred revenue decreased by 17.3% year-over-year, from $39.65M to $32.79M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s deferred revenue?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s deferred revenue has grown at a 30.3% compound annual growth rate (CAGR), from $10M to $37.61M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.